tiprankstipranks
United Therapeutics (CH:UTH)
:UTH
Switzerland Market

United Therapeutics (UTH) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

UTH Analyst Ratings

Strong Buy
9Ratings
Strong Buy
7 Buy
2 Hold
0 Sell
Based on 9 analysts giving stock ratings to
United
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

UTH Stock 12 Month Forecast

Average Price Target

Based on 9 Wall Street analysts offering 12 month price targets for United Therapeutics in the last 3 months. The average price target is CHF525.25 with a high forecast of CHF572.46 and a low forecast of CHF412.91. The average price target represents a change from the last price of .
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
Highest Price TargetCHF572.46Average Price TargetCHF525.25Lowest Price TargetCHF412.91
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on CH:UTH
RBC Capital
RBC Capital
CHF542.79
Buy
Reiterated
08/25/26
RBC Capital Sticks to Its Buy Rating for United Therapeutics (UTHR)
TD Cowen Analyst forecast on CH:UTH
TD Cowen
TD Cowen
CHF541.19
Buy
Reiterated
08/24/26
Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR) and AdaptHealth (NASDAQ: AHCO)
Wells Fargo Analyst forecast on CH:UTH
Wells Fargo
Wells Fargo
CHF561.23
Buy
Reiterated
08/19/26
Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Lifestance Health Group (NASDAQ: LFST) and Avita Medical (NASDAQ: RCEL)
H.C. Wainwright Analyst forecast on CH:UTH
H.C. Wainwright
H.C. Wainwright
CHF529.16
Buy
Reiterated
08/06/26
Buy Rating Reiterated on United Therapeutics as Diversified Pipeline Offsets Near-Term Headwinds; $660 Price Target Maintained
Morgan Stanley Analyst forecast on CH:UTH
Morgan Stanley
Morgan Stanley
CHF413.71CHF412.91
Hold
Assigned
08/06/26
Morgan Stanley Reaffirms Their Hold Rating on United Therapeutics (UTHR)
J.P. Morgan Analyst forecast on CH:UTH
J.P. Morgan
J.P. Morgan
CHF550.81
Buy
Reiterated
07/23/26
Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Biogen (NASDAQ: BIIB) and Community Health (NYSE: CYH)
Bank of America Securities Analyst forecast on CH:UTH
Bank of America Securities
Bank of America Securities
CHF497.09CHF491.48
Hold
Reiterated
07/10/26
Bank of America Securities Reaffirms Their Hold Rating on United Therapeutics (UTHR)
Jefferies Analyst forecast on CH:UTH
Jefferies
Jefferies
CHF587.69CHF572.46
Buy
Reiterated
07/10/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Leerink Partners Analyst forecast on CH:UTH
Leerink Partners
Leerink Partners
Buy
Reiterated
06/29/26
FDA premarket approval of LungFX positive for United Therapeutics, says LeerinkFDA premarket approval of LungFX positive for United Therapeutics, says Leerink
Raymond James Analyst forecast on CH:UTH
Raymond James
Raymond James
CHF561.23
Buy
Initiated
04/09/26
United Therapeutics initiated with an Outperform at Raymond JamesUnited Therapeutics initiated with an Outperform at Raymond James
Cantor Fitzgerald Analyst forecast on CH:UTH
Cantor Fitzgerald
Cantor Fitzgerald
CHF420.92CHF501.1
Buy
Initiated
03/12/26
Cantor Fitzgerald Reaffirms Their Buy Rating on United Therapeutics (UTHR)
UBS
CHF525.15CHF565.24
Buy
Assigned
03/05/26
Analysts Conflicted on These Healthcare Names: Veeva Systems (NYSE: VEEV) and United Therapeutics (NASDAQ: UTHR)
Argus Research Analyst forecast on CH:UTH
Argus Research
Argus Research
CHF448.99
Buy
Assigned
03/03/26
United Therapeutics price target raised to $560 from $500 at ArgusUnited Therapeutics price target raised to $560 from $500 at Argus
BTIG
Hold
Reiterated
02/25/26
Balancing Franchise Headwinds and Pipeline Upside: Rationale Behind a Hold on United Therapeutics
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on CH:UTH
RBC Capital
RBC Capital
CHF542.79
Buy
Reiterated
08/25/26
RBC Capital Sticks to Its Buy Rating for United Therapeutics (UTHR)
TD Cowen Analyst forecast on CH:UTH
TD Cowen
TD Cowen
CHF541.19
Buy
Reiterated
08/24/26
Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR) and AdaptHealth (NASDAQ: AHCO)
Wells Fargo Analyst forecast on CH:UTH
Wells Fargo
Wells Fargo
CHF561.23
Buy
Reiterated
08/19/26
Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Lifestance Health Group (NASDAQ: LFST) and Avita Medical (NASDAQ: RCEL)
H.C. Wainwright Analyst forecast on CH:UTH
H.C. Wainwright
H.C. Wainwright
CHF529.16
Buy
Reiterated
08/06/26
Buy Rating Reiterated on United Therapeutics as Diversified Pipeline Offsets Near-Term Headwinds; $660 Price Target Maintained
Morgan Stanley Analyst forecast on CH:UTH
Morgan Stanley
Morgan Stanley
CHF413.71CHF412.91
Hold
Assigned
08/06/26
Morgan Stanley Reaffirms Their Hold Rating on United Therapeutics (UTHR)
J.P. Morgan Analyst forecast on CH:UTH
J.P. Morgan
J.P. Morgan
CHF550.81
Buy
Reiterated
07/23/26
Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Biogen (NASDAQ: BIIB) and Community Health (NYSE: CYH)
Bank of America Securities Analyst forecast on CH:UTH
Bank of America Securities
Bank of America Securities
CHF497.09CHF491.48
Hold
Reiterated
07/10/26
Bank of America Securities Reaffirms Their Hold Rating on United Therapeutics (UTHR)
Jefferies Analyst forecast on CH:UTH
Jefferies
Jefferies
CHF587.69CHF572.46
Buy
Reiterated
07/10/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Leerink Partners Analyst forecast on CH:UTH
Leerink Partners
Leerink Partners
Buy
Reiterated
06/29/26
FDA premarket approval of LungFX positive for United Therapeutics, says LeerinkFDA premarket approval of LungFX positive for United Therapeutics, says Leerink
Raymond James Analyst forecast on CH:UTH
Raymond James
Raymond James
CHF561.23
Buy
Initiated
04/09/26
United Therapeutics initiated with an Outperform at Raymond JamesUnited Therapeutics initiated with an Outperform at Raymond James
Cantor Fitzgerald Analyst forecast on CH:UTH
Cantor Fitzgerald
Cantor Fitzgerald
CHF420.92CHF501.1
Buy
Initiated
03/12/26
Cantor Fitzgerald Reaffirms Their Buy Rating on United Therapeutics (UTHR)
UBS
CHF525.15CHF565.24
Buy
Assigned
03/05/26
Analysts Conflicted on These Healthcare Names: Veeva Systems (NYSE: VEEV) and United Therapeutics (NASDAQ: UTHR)
Argus Research Analyst forecast on CH:UTH
Argus Research
Argus Research
CHF448.99
Buy
Assigned
03/03/26
United Therapeutics price target raised to $560 from $500 at ArgusUnited Therapeutics price target raised to $560 from $500 at Argus
BTIG
Hold
Reiterated
02/25/26
Balancing Franchise Headwinds and Pipeline Upside: Rationale Behind a Hold on United Therapeutics
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering United Therapeutics

3 Months
Roanna RuizLeerink Partners
Success Rate
15/18 ratings generated profit
83%
Average Return
+15.31%
Copying Roanna Ruiz's trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +15.31% per trade.
1 Year
Roger SongJefferies
Success Rate
12/14 ratings generated profit
86%
Average Return
+27.13%
Copying Roger Song's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +27.13% per trade.
2 Years
Success Rate
15/15 ratings generated profit
100%
Average Return
+35.47%
Copying Ashwani Verma's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +35.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

UTH Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
21
24
15
16
14
Hold
11
9
5
4
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
33
20
20
17
In the current month, UTH has received 14 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. UTH average Analyst price target in the past 3 months is 525.25.
Each month's total comprises the sum of three months' worth of ratings.

UTH Financial Forecast

UTH Earnings Forecast

Next quarter’s earnings estimate for UTH is CHF5.18 with a range of CHF3.54 to CHF6.14. The previous quarter’s EPS was CHF5.85. UTH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year UTH has Performed in-line its overall industry.
Next quarter’s earnings estimate for UTH is CHF5.18 with a range of CHF3.54 to CHF6.14. The previous quarter’s EPS was CHF5.85. UTH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year UTH has Performed in-line its overall industry.

UTH Sales Forecast

Next quarter’s sales forecast for UTH is CHF635.74M with a range of CHF604.74M to CHF666.74M. The previous quarter’s sales results were CHF630.75M. UTH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year UTH has Performed in-line its overall industry.
Next quarter’s sales forecast for UTH is CHF635.74M with a range of CHF604.74M to CHF666.74M. The previous quarter’s sales results were CHF630.75M. UTH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year UTH has Performed in-line its overall industry.

UTH Stock Forecast FAQ

What is CH:UTH’s average 12-month price target, according to analysts?
Based on analyst ratings, United Therapeutics’s 12-month average price target is 525.25.
    What is CH:UTH’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:UTH, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is United Therapeutics a Buy, Sell or Hold?
        United Therapeutics has a consensus rating of Strong Buy, which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.
          What is United Therapeutics’s share price target?
          The average share price target for United Therapeutics is 525.25. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF572.46 ,and the lowest forecast is CHF412.91. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about United Therapeutics?
            United Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
              How can I buy shares of United Therapeutics?
              To buy shares of CH:UTH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.